Nutriband Founder Returns as CEO to Lead Final Development of Abuse-Deterrent Fentanyl Patch
TL;DR
Nutriband's founder returns as CEO to lead AVERSA Fentanyl development, targeting $80-200M annual US sales with patented abuse-deterrent technology in 46 countries.
Nutriband's AVERSA technology incorporates abuse-deterrent features into transdermal patches to prevent misuse, with an NDA filing planned for 2026 after final development.
AVERSA Fentanyl's abuse-deterrent design helps prevent opioid misuse and accidental exposure, creating safer pain management options for patients and communities.
Nutriband's patented AVERSA technology transforms transdermal patches into abuse-deterrent systems protected across 46 countries including the US, Europe, and Japan.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc. founder Gareth Sheridan has returned to his position as chief executive officer, taking leadership of the company during the crucial final development phase of its flagship AVERSA Fentanyl abuse-deterrent opioid patch. The leadership transition comes as the company prepares for an expected 2026 New Drug Application filing, positioning the innovative pain management solution for potential market entry.
The timing of Sheridan's return underscores the strategic importance of advancing AVERSA Fentanyl through its final development framework toward commercialization. The patch represents a significant advancement in opioid safety technology, designed specifically to deter misuse and prevent accidental exposure to the powerful pain medication. This development comes at a critical juncture in healthcare, as the opioid crisis continues to claim thousands of lives annually through overdose and misuse of prescription medications.
AVERSA Fentanyl's market potential is substantial, with peak annual U.S. sales estimated between $80 million and $200 million. The technology's broad patent protection across 46 countries, including the United States, Europe, and Japan, provides Nutriband with significant competitive advantages and market exclusivity potential. The company's transdermal delivery platform represents a novel approach to addressing one of healthcare's most pressing challenges.
The AVERSA technology platform can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This versatility suggests potential applications beyond fentanyl, potentially extending to other controlled substances where abuse deterrence is a critical safety concern. Additional information about the company and its development pipeline is available through its corporate website at https://www.nutriband.com.
Investors and stakeholders can access the latest corporate updates and regulatory developments through the company's dedicated newsroom at https://ibn.fm/NTRB. The full details of the leadership announcement and corporate strategy are available in the official press release at https://ibn.fm/3r3N9.
The development of abuse-deterrent formulations represents a critical frontier in pharmaceutical innovation, particularly for opioids where the balance between effective pain management and safety remains challenging. AVERSA Fentanyl's progress through development stages signals potential relief for healthcare providers seeking safer alternatives for patients requiring potent pain management while addressing regulatory and public health concerns about opioid safety.
Curated from InvestorBrandNetwork (IBN)
